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Abstract: Mesenchymal stem/progenitor cells (MSPCs) have recently gained attention as key 
elements that contribute at different stages in oncogenesis, from predisposition to disease 
manifestation and evolution. In this issue of Cell Stem Cell, Zambetti, Ping, Chen et al. propose a 
mechanism by which mutated MSPCs transform hematopoietic cells into a malignant-prone state 
(Zambetti et al., 2016). 
 
Text: MSPCs represent an important component of the specialized microenvironment (niche) where 
normal and leukemic hematopoietic stem and progenitor cells (HSPCs) reside in the bone marrow 
(BM). 
 
Although many identified driver mutations in HSPCs can initiate leukemia, alterations in HSPC niches 
might contribute to leukemogenesis by providing a fertile ground for the acquisition of additional 
mutations, the selection of mutated clones, or impaired hematopoiesis in normal cells, which provides 
a competitive advantage to preleukemic cells. 
 
A recent paper from the Raaijmakers lab (Zambetti et al., 2016) presented in this issue of Cell Stem 
Cell proposes a mechanism by which the transformed niche can trigger abnormal hematopoiesis and 
the accumulation of leukemic-prone HSPCs. The authors approached this question in Shwachman-
Diamond Syndrome (SDS), a rare congenital disorder characterized in humans by low bone mass 
(osteoporosis) and a tendency to progress from ineffective blood cell production (myelodysplasia) to 
excessive proliferation of myeloid cells (myeloproliferation) and secondary leukemia. Human SDS 
carries an inactivating mutation in the Shwachman-Bodian-Diamond Syndrome gene (SBDS), which 
encodes a ribosomal maturation protein. Like other mutations affecting ribosomal biogenesis (named 
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‘‘ribosomopathies’’), SDS matches the ‘‘Dameshek’s riddle,’’ which highlights the paradoxical and still 
incompletely understood transition from a hypo- proliferative stage to a hyper-proliferative phase in 
these and other disorders (De Keersmaecker et al., 2015). Also, the consequences of the Sbds 
mutation in each cell type and their relative contribution in SDS have remained unclear. 
 
In a previous study, the Raaijmakers lab specifically deleted Sbds in HSPCs expressing the myeloid 
transcription factor CCAAT/enhancer binding protein alpha (Cebpa). Sbds deletion activated the p53 
tumor suppressor and caused apoptosis in the myeloid cells, leading to a decreased number of 
neutrophils, but  it did not cause myelodysplasia or leukemia (Zambetti et al., 2015). To study the 
contribution of the mutated microenvironment, Raaijmakers et al. deleted the Sbds gene in osterix+ 
MSPCs in another previous study. Sbds deficiency in MSPCs caused skeletal abnormalities, 
myelodysplasia and sporadic leukemic transformation (Raaijmakers et al., 2010). This landmark study 
was among the first to show that alterations in specific niche cells can be leukemogenic. However, the 
underlying mechanisms had remained unclear so far. 
 
The new study (Zambetti et al., 2016) shows structural and mechanical defects in mice lacking Sbds in 
MSPCs (Osxcre Sbdsf/f) similar to the osteoporosis observed in human SDS. Gene ex- pression profiling 
of MSPCs suggested impaired osteogenic differentiation, leading to reduced numbers of bone-forming 
cells, which might explain the skeletal abnormalities. Interestingly, HSPC number and function were 
not altered. However, gene expression analysis identified signatures associated with leukemic 
evolution of human CD34+ cells, which included mitochondrial abnormalities. In fact, HSPCs from mice 
lacking Sbds in MSPCs contained hyperpolarized mitochondria that caused increased reactive oxygen 
species (ROS) and DNA double-strand breaks, which were marked by accumulation of Ser139-
phosphorylated H2AX his- tone. Therefore, the absence of Sbds in MSPCs can cause genotoxic stress 
and activate DNA damage response (DDR) and DNA repair pathways in HSPCs, leading to cell-cycle 
arrest and apoptosis. In future studies, it will be interesting to explore how HSPCs cope with such high 
ROS levels and whether other BM niche cells contribute to the ability to withstand the genotoxic 
environment. 
 
To elucidate the MSPC-driven induction of genotoxic stress in HSPCs, the authors focused on p53, 
which had been previously implicated in ribosomopathies. They found increased p53 expression and 
activation of its downstream pathways in Sbds-deleted MSPCs. Importantly, both the skeletal and the 
mitochondrial phenotypes were partially rescued in mice simultaneously lacking Sbds and p53 in 
MSPCs. To search for candidate p53 targets, they compared the transcriptional profiles of Sbds-
 3 
deficient murine MSPCs and CD271+ MSPCs from human SDS with normal controls. They found 40 
genes that were differentially expressed in both murine and human Sbds-deficient MSPCs. To further 
investigate the genes responsible for the hematopoietic abnormalities, they compared the 
transcriptional profile of SDS patients with that of two other related human diseases: low- risk 
myelodysplastic syndrome (MDS)— a preleukemic disorder with concomitant high ROS, DNA, damage 
and apoptosis—and Diamond Blackfan anemia (DBA; a ribosomopathy with BM failure but less prone 
to leukemic transformation than SDS). The rationale was to find genes implicated both in SDS and 
MDS –but not in DBA– as candidate drivers of leukemia predisposition. The genes encoding the S100 
calcium-binding protein A8/A9 –p53 targets– were likely candidates, given their high expression in 
Sbds-deficient MSPCs and their known role in MDS patients (Chen et al., 2013). 
 
S100A8/A9 are secreted   inflammatory   molecules   that activate Toll-like receptor 4 (Tlr4) and it’s 
downstream mediator nuclear factor-kB, leading to increased expression of Tumor necrosis factor 
(TNF)a (Vogl et al., 2007). Through experiments involving S100A8/A9 overexpression and inhibition, 
Zambetti et al.  confirmed MSPC-derived S100A8/A9’s capacity to induce genotoxic stress in both 
murine and human HSPCs (Figure 1). 
 
Finally, the potential clinical relevance of niche S100A8/A9 expression in leukemogenesis was 
elegantly demonstrated after discovering a significantly higher risk of leukemic evolution in MDS 
patients who were classified as low-risk yet presented BM niches that were characterized by high 
expression of S100A8/A9. 
 
The possibility that non-hematopoietic mutations might initiate myeloproliferative disorders is not 
new. This concept was first suggested in newborn mice lacking the nuclear factor of kappa light 
polypeptide gene enhancer in B cells inhibitor alpha (IkBa) (Rupec et al., 2005). The 
myeloproliferative disorder observed in Ik Ba-null mice was not recapitulated by specific IkBa deletion 
in myeloid and fetal liver cells. The confirmation of this initiation potential came 2 years later, when 
deletion of retinoic acid receptor gamma (RARg) in the hematopoietic microenvironment caused a 
TNFa-dependent myeloproliferative disorder (Walkley et al., 2007). Raaijmakers, Scadden, and 
colleagues refined the microenvironmental contributions and demonstrated that, under certain 
conditions, MSPCs can initiate myeloid malignancies. Deletion of the RNA processing enzyme Dicer1 in 
MSPCs caused MDS- like disease with sporadic transformation to AML. Loss of Dicer1 in MSPCs caused 
reduced Sbds expression (Raajimakers et al., 2010), Interestingly, reduced ex- pression of DICER and 
SBDS has been noted in MSPCs from MDS patients, suggesting potential similarities with the hu- man 
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disease (Santamaria et al., 2012). These and other studies that cannot be discussed due to space 
constraints suggest potential commonalities: bone loss and transient HSPC reduction were observed 
in mice lacking Dicer1 or Sbds in MSPCs and in those with a RARg-deficient BM microenvironment. 
Moreover, S100A8/A9-activated Tlr4 can increase TNFa, and both are required for Sbds- and  RARg-
deficient  microenvironmental. malignancies. In turn, this inflammatory environment can also damage 
essential HSPC niche components, therefore facilitating disease progression (Arranz et al., 2014). 
Overall, these studies indicate that BM inflammation (which can be caused by mutated MSPCs) 
facilitates myeloproliferation and increases the risk of leukemic transformation. 
 
Whereas it is considered that HSPC mutations are generally necessary for leukemia development, 
these and other future studies of preleukemic stages will determine whether functional and/or 
genetic microenvironmental alterations facilitate the acquisition of additional hematopoietic 
mutations and/or confer a competitive advantage to mutated clones, thereby providing a fertile 
ground for genotoxicity and/or clonal selection, respectively. 
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